*Guest blog by Pivotal. For more information on the information in this blog post please contact Ms. Natalia Farr - [email protected]. If you would like to submit a guest blog please email [email protected].
The AI revolution in Pharmaceutical R&D is transitioning from experimental curiosity to operational necessity. This transformation is supported by quantifiable operational improvements: AI-enabled discovery workflows have shown the potential to reduce early discovery timelines by up to 40% and costs by approximately 30% for complex targets [1].
The strategic role of…
For many Life Sciences companies, R&D tax relief has long been viewed as a mechanism for recovering cost; an incentive aligned with innovation, growth, and scientific ambition.
That framing is no longer sufficient.
Over the past 18–24 months, we have seen a clear shift in how R&D claims in the Life Sciences sector are reviewed and challenged by HMRC. The focus has moved decisively away from the size of a claim and towards its technical credibility, evidential support, and internal consistency.
For finance leaders and R&D teams alike, this marks an important change in…
As we approach a new financial year, five months on from the launch of the Charities Aid Foundation's latest Corporate Giving Report, its message remains powerful: corporate giving is declining, yet it remains a central pillar to responsible business.
You may be wondering who the Charities Aid Foundation are? The Charities Aid Foundation (CAF) are a global charity working with individual and corporate donors to turn their generosity, connection to a cause and ambition, into purposeful change. We help businesses, including those in the life sciences sector, to give to charities around the…
R&D Tax Credit Pre-Notification: A Critical Requirement for Innovators
Pre-notification is now a mandatory legislative requirement for certain companies intending to claim R&D tax credits. Introduced as part of HMRC’s reforms to the R&D tax relief regime, the rule applies to companies that are first-time claimants or those that have not made a relevant R&D tax credit claim in the previous three accounting periods. Affected companies must notify HMRC of their intention to claim within six months of the end of the relevant accounting period.
If this deadline is missed, the…
by Philippa Clark, Director of Business Development, One Nucleus
As we start 2026, it’s easy to focus on the next wave of exciting science: artificial intelligence, data-driven discovery and new therapeutic platforms. All of this absolutely matters, but I increasingly believe the future of life sciences will be shaped less by what we invent and more by how well we align the ecosystems around it. The life sciences sector does not lack activity but can lack connection.
Across life sciences, we still operate in silos at a sector level. Science moves forward, then funding follows later,…
By Philippa Clark, Director of Business Development, One Nucleus
Pitching is often treated as something founders do only when they are raising money, yet in life sciences it has become far more than a fundraising exercise. It has turned into one of the most adaptable tools a company has, influencing how it is perceived, supported and championed long before any investment round begins.
As we head towards Genesis 2025 and the launch of the new Company Showcase stream, I’ve been thinking about how much broader the value of pitching has become. Securing capital will always matter, it is what…
By LimestoneGrey, Chartered Tax Advisers specialising in R&D tax relief
Many companies working within the Med-Tech and life sciences sectors are tackling global challenges such as antimicrobial resistance, ageing populations and chronic disease management. Addressing these complex issues often requires research that extends beyond the UK's borders.
However, as part of major reforms to R&D tax relief, the government has now imposed strict limits on the eligibility of overseas expenditure. The new rules aim to encourage domestic innovation, meaning that, by default, most overseas R…
By Tony Jones, CEO, One Nucleus
It is not difficult to see how challenging recent times have been in raising capital for nascent life science companies no matter where they are located. There have always been regional differences in dynamics and financing cycles, but these have to some degree been overshadowed more recently, with almost every location seeing entrepreneurs and leadership teams struggle to secure capital, particularly at the early stages.
Data from the BIA
The latest BIA BioFinancing Report covering July-September 2025 did not necessarily offer much comfort, as one of…
Labs using AI in their supply chains are seeing serious gains. Think a 35% reduction in inventory levels, 15% lower logistics costs, and $300 million in savings by predicting stock risks before they happen. The secret? Smart automation.
Artificial intelligence (AI) is transforming how life science labs manage procurement, from forecasting inventory needs to streamlining vendor selection. Tasks that once required hours of manual effort, like comparing prices, coordinating orders, and pulling spend information, can now be done in minutes.
As the biotech and pharma landscape becomes increasingly…
Breast cancer continues to affect millions worldwide, not just as statistics, but as mothers, sisters, daughters, and friends. Its biological complexity and diverse subtypes make therapy development especially challenging, particularly for metastatic disease, the leading cause of breast cancer mortality.
BioDuro’s CDX (Cell-Derived Xenograft) model platform offers a comprehensive library of preclinical breast cancer models that reflect real-world tumor heterogeneity. These models enable researchers to:
Investigate metastasis mechanisms in clinically relevant systems
Evaluate targeted…